SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring had been serving as a financial consultant to the Company since December 2024. The appointment strengthen ...

SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of A ...

Core Viewpoint - Artelo Biosciences, Inc. has successfully closed a public offering of common stock and pre-funded warrants, raising approximately $3.0 million to support its clinical-stage pharmaceutical initiatives focused on lipid-signaling pathways for various medical conditions [1][2]. Group 1: Offering Details - The company offered 640,924 shares of common stock at a public price of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at a price of $4.399 per warrant [1]. - The gross proceeds from the offering were approximately $3.0 million before deducting underwriting discounts and other expenses [2]. - Underwriters were granted a 45-day option to purchase an additional 102,272 shares at the public offering price to cover over-allotments [2]. Group 2: Regulatory and Documentation - The shares and warrants were offered under a "shelf" registration statement on Form S-3, which was filed with the SEC on July 6, 2023, and declared effective on July 14, 2023 [3]. - The final prospectus supplement and accompanying base prospectus were filed with the SEC on September 5, 2025, and are available on the SEC's website [4]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, addressing significant unmet needs in various medical conditions including cancer and pain [7]. - The company has adopted a corporate finance initiative to deploy excess capital into digital assets as part of its treasury strategy [7].